MARKET

ATRC

ATRC

AtriCure
NASDAQ

Real-time Quotes | Nasdaq Last Sale

46.91
+2.38
+5.34%
After Hours: 46.91 0 0.00% 16:01 07/15 EDT
OPEN
45.25
PREV CLOSE
44.53
HIGH
48.16
LOW
45.25
VOLUME
467.15K
TURNOVER
--
52 WEEK HIGH
51.76
52 WEEK LOW
22.57
MARKET CAP
2.07B
P/E (TTM)
-38.9942
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ATRC stock price target is 54.29 with a high estimate of 63.00 and a low estimate of 47.00.

EPS

ATRC News

More
AtriCure to Announce Second Quarter 2020 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2020 financial results on Tuesday, July 28, 2020.
Business Wire · 07/07 12:00
Hedge Funds Are Buying AtriCure Inc. (ATRC)
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. I
Insider Monkey · 06/19 16:45
Edited Transcript of ATRC.OQ earnings conference call or presentation 29-Apr-20 8:30pm GMT
Q1 2020 AtriCure Inc Earnings Call
Thomson Reuters StreetEvents · 06/17 08:53
The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18)
Benzinga · 05/19 12:27
Stocks That Hit 52-Week Highs On Monday
During the morning session on Monday, 120 stocks hit new 52-week highs.
Benzinga · 05/18 14:44
Stocks That Hit 52-Week Highs On Wednesday
This morning 35 companies set new 52-week highs.
Benzinga · 05/13 14:35
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12)
Benzinga · 05/13 11:40
Protalix Fabry Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 05/12 18:09

Industry

Medical Equipment, Supplies & Distribution
+3.30%
Healthcare Equipment & Supplies
+2.97%

Hot Stocks

Symbol
Price
%Change

About ATRC

AtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage (LAA).
More

Webull offers kinds of AtriCure Inc. stock information, including NASDAQ:ATRC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATRC stock methods without spending real money on the virtual paper trading platform.